Impact Of Diabetes Prevalence On The Insulin Delivery Devices Market: Strategic Insights Driving Insulin Delivery Devices Market Momentum in 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Insulin Delivery Devices Market Size By 2025?
Over the past few years, the insulin delivery devices market has seen robust growth. This growth is set to continue, with market size expected to rise from $17.71 billion in 2024 to $19.07 billion in 2025, representing a compound annual growth rate (CAGR) of 7.7%. Factors contributing to this historical growth include the convenience and user-friendliness of insulin delivery devices, beneficial reimbursement policies, the rising occurrence of obesity, an increasing elderly population, and the growing preference for insulin pumps.

How Big Is the Insulin Delivery Devices Market Size Expected to Grow by 2029?
The market for insulin delivery devices is predicted to significantly surge over the coming years, with a target size of $25.98 billion in 2029 at a compound annual growth rate (CAGR) of 8.0%. This anticipated boost within the projected timeline can be traced back to the increasing instances of diabetes, higher healthcare spending on diabetes treatment, the proliferation of continuous glucose monitoring systems, enhanced patient understanding of the benefits of automated insulin delivery devices, and a heightened emphasis on healthcare. The forecast period is set to witness various emerging trends including technological improvements in insulin delivery devices, the fusion of digital technology with such devices, the creation of artificial pancreas systems, breakthroughs in insulin application technology, and strides in bionic technology.

View the full report here:
https://www.thebusinessresearchcompany.com/report/insulin-delivery-devices-global-market-report

Which Key Market Drivers Powering Insulin Delivery Devices Market Expansion and Growth?
The rise in diabetes instances is anticipated to boost the insulin delivery devices market. Diabetes is a long-term ailment characterized by elevated blood sugar levels, either due to insufficient insulin production by the pancreas or the body's failure to effectively use insulin. Sedentary lifestyles, unhealthy eating habits, and the global increase in obesity rates are primarily responsible for the rise in diabetes rates. Insulin delivery devices, critical for diabetes management, help patients regulate their blood sugar levels by facilitating the controlled and convenient administration of insulin. This aids in averting complications and promoting health. For example, the Centers for Disease Control and Prevention, a US government organization, projected in December 2022 that the number of type 2 diabetes cases in individuals under age 20 in the United States could grow by almost 700% by 2060, possibly impacting 220,000 individuals. The diagnoses of type 1 diabetes among children could also increase by up to 65% over the same timeline. Consequently, the escalating prevalence of diabetes fuels the insulin delivery devices market expansion.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=18642&type=smp

What Are the Key Trends Driving Insulin Delivery Devices Market Growth?
Prominent corporations in the insulin delivery devices market are driving innovation by creating advanced products like insulin pumps that offer regular or adjustable insulin supply. Insulin pumps are adjustable medical devices that transfer insulin in a steady stream or on an as-needed basis via a catheter under the skin. For instance, US medical technology firm Beta Bionics announced in May 2023 that it had received approval from the U.S. Food and Drug Administration for the iLet ACE Pump and the iLet Dosing Decision Software. The iLet Bionic Pancreas system, designed for those aged six and older with type 1 diabetes, uses two devices along with an FDA-approved integrated continuous glucose monitor (iCGM). It features an automated insulin dosing (AID) system powered by an adaptive closed-loop algorithm that only requires the patient's weight for setup, thereby eliminating the need for further insulin dosing variables. This system is unique as it does not require manual adjustment, making initiation and management easier. Furthermore, the iLet device has a novel meal announcement feature that simplifies mealtime insulin dosing by classifying meals into small, medium, or large, allowing the algorithm to learn and adjust to the individual's insulin demands over time.

What Are the Emerging Segments in the Insulin Delivery Devices Market?
The insulin delivery devices market covered in this report is segmented -

1) By Type: Insulin Syringes, Insulin Jet Injectors, Pen Needles, Reusable Insulin Pens, Disposable Insulin Pens, Insulin Pumps, External Or Tethered Pumps, Patch Pumps
2) By Disease Indication: Type 1, Type 2
3) By Distribution Channels: Hospital Pharmacies, Retail Pharmacies, Online Sales, Diabetes Clinics Or Centers

Subsegments:
1) By Insulin Syringes: Standard Insulin Syringes, Insulin Syringes With Fixed Or Adjustable Needle Length
2) By Insulin Jet Injectors: Needle-Free Insulin Jet Injectors, High-Pressure Insulin Jet Injectors
3) By Pen Needles: Short Pen Needles, Long Pen Needles
4) By Reusable Insulin Pens: Reusable Pens With Replaceable Cartridges, Refillable Insulin Pens
5) By Disposable Insulin Pens: Single-Use Disposable Insulin Pens, Pre-Filled Disposable Insulin Pens
6) By Insulin Pumps: Traditional Insulin Pumps, Smart Insulin Pumps
7) By External Or Tethered Pumps: Traditional External Insulin Pumps, Wireless Tethered Pumps
8) By Patch Pumps: Patch Insulin Pumps, Integrated Patch Pumps

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=18642&type=smp

Who Are the Global Leaders in the Insulin Delivery Devices Market?
Major companies operating in the insulin delivery devices market are Sanofi SA, Abbott Laboratories, F. Hoffmann-La Roche Ltd., Medtronic Plc, Eli Lilly and Company, Novo Nordisk A/S, Becton, dic*kinson and Company, EOFlow Co. Ltd., Insulet Corporation, Tandem Diabetes Care Inc., Ypsomed Holding AG, Xeris Pharmaceuticals Inc., Beta Bionics Inc., Zealand Pharma AS, Bigfoot Biomedical Inc., Emperra GmbH, Animas Corporation, Debiotech SA, CeQur Corporation, Aerami Therapeutics Inc., Alshifa Medical Group, AMF Medical SA, Andain Inc., Avecho Biotechnology Ltd., Apex Medical Devices

Which are the Top Profitable Regional Markets for the Insulin Delivery Devices Industry?
North America was the largest region in the insulin delivery devices market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the insulin delivery devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=18642

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.